The week in pharma: action, reaction and insight – week to August 1

3 August 2025

By Barbara Obstoj-Cardwell

Among last week’s news, US biotech Celcuity leapt 180% on new Phase III data for its cancer drug candidate gedatolisib. US drugmaker Madrigal Pharmaceuticals entered into a licensing deal with China’s CSPC Pharma for rights to a GLP-1 receptor inhibitor, SYH 2086, to compliment its platform in metabolic dysfunction associated steatohepatitis (MASH) – led by Rezdiffra. US President Donald Trump issued an ultimatum to a number of major pharmaceutical companies demanding that they reduce the price of their drugs in the USA. Also of note, LENZ Therapeutics received US Food and Drug Administration (FDA) approval for its VIZZ, the first aceclidine-based drug for the treatment of presbyopia in adults.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK